Core Viewpoint - Peijia Medical (09996) has seen a significant increase in its stock price, rising over 22% in December, with a current price of 6.35 HKD and a trading volume of 10.9 million HKD [1] Group 1: Company Developments - On December 5, Peijia Medical announced that Chairman Dr. Zhang Yi plans to invest up to 15 million HKD to buy back company shares in the open market [1] - On December 11, Peijia Medical received approval from the National Medical Products Administration for its TaurusTrio transcatheter aortic valve system, marking it as the first integrated positioning key transcatheter aortic valve regurgitation (AR) intervention device approved in China [1] Group 2: Market Position and Future Outlook - According to a report from CITIC Securities, Peijia Medical holds a leading position in the domestic heart valve intervention market, with positive clinical feedback and rapid market share growth since the commercialization of its TAVR products [1] - The company has a comprehensive product development pipeline in the aortic, mitral, and tricuspid valve treatment areas, which is expected to strengthen its leading position in the heart valve sector [1] - Peijia Medical anticipates the approval and commercialization of three major products in China by the end of 2025 to 2026, which will support a rapid recovery in overall performance [1] - The company's neurointerventional business is among the top domestic players, and with a continuously enriching product pipeline and ongoing commercialization of certified products, it is expected to maintain a trend of rapid development [1]
沛嘉医疗-B再涨超6% 董事长增持彰显信心 旗下TaurusTrio近日获批上市